Background <p>CD8 T cells mediate the effects of cancer immunotherapies. CD8 positron emission tomography (PET) imaging with [<sup>89</sup>Zr]Zr-berdoxam-crefmirlimab enables whole body CD8 cell assessment and has been shown to be safe in Phase I evaluation. The correlation between CD8 PET imaging parameters and the quantity of CD8 cells assessed by the gold standard of immunohistochemistry (IHC) is unknown.</p> Methods <p>The…
CD8 PET imaging with [89Zr]Zr-berdoxam-crefmirlimab in patients with solid tumors: the Phase II iCorrelate study
Journal for ImmunoTherapy of Cancer | | Postow, M. A., Zang, P. D., Pal, S. K., Mauguen, A., Farwell, M., Gordon, M., Hays, D., Wong, J. Y. C., Chen, D., Ulaner, G. A., Esposito, G., McConathy, J., Graham, M. M., Shields, A. F., Van den Abbeele, A. D., Butler, M. O., Thomas, J. S., Twardowski, P., Narang, J., Singh, A. P., Dey, A., Maresca, K. P., Keliher, E., Liu, F., Potdevin, G., Schmidt, G., Le, W., Wilson, I., Mascioni, A., Jia, F., Korn, R., Ferris, M. R., Schmiedehausen, K., Pandit-Taskar, N., Margolin, K. A.
Topics: clinical-trials, research
Read the full article at Journal for ImmunoTherapy of Cancer